Cipla : Orchid Pharma partners with Cipla to launch antibiotic Cefepime - Enmetazobactam in India

About this update from Cipla Ltd

Orchid Pharma partners with Cipla to launch antibiotic Cefepime- Enmetazobactam in India This strategic alliance aims to rapidly deploy Orchid's novel anti-infective invented in India to address the rising threat of antimicrobial resistance (AMR) New Delhi, June 28, 2024 : Orchid Pharma Limited, ('Orchid Pharma') based in Chennai, India, the only Indian pharmaceutical company to have ever invented a New Chemical Entity (NCE), today announced the launch of its new drug - Cefepime-Enmetazobactam, which has been approved for the treatment of complicated Urinary Tract infections (cUTI), Hospital-Acquired Pneumonia (HAP) and Ventilator-Associated Pneumonia (VAP) indications. In a landmark collaboration, Orchid Pharma has partnered with Cipla Limited ('Cipla') to ensure widespread and rapid distribution of this breakthrough antibiotic combination across India. The launch of Cefepime-Enmetazobactam marks a significant milestone for India's pharmaceutical industry in the fight against AMR, a growing global health issue, reinforcing India's leadership in medical innovation. Orchid Pharma and Cipla are confident that this collaboration will set a new benchmark for addressing critical healthcare challenges through strategic partnerships and advanced research. The partnership between Orchid Pharma and Cipla combines Orchid's innovative drug development capabilities with Cipla's extensive distribution network and market presence. This collaboration aims to ensure that this life-saving medication reaches healthcare providers across India as quickly and efficiently as possible. Speaking on the launch, Mr. Manish Dhanuka, Managing Director Orchid Pharma said, "With increasing resistance to the current drugs most commonly used for treatment of these indications e.g. Piperacillin-Tazobactam for cUTI - doctors were forced to start using Carbapenems - a reserve drug meant to be used when most other drugs don't work. Now, Orchid's Cefepime- Enmetazobactam will allow doctors to spare Carbapenems, prolonging their effective life by restricting their use." Mr. Umang Vohra, Managing Director & Global Chief Executive Officer, Cipla, said, "AMR is an urgent and serious healthcare challenge that needs global attention. With the rising incidence of potentially-life threatening infections, there is a strong need for novel anti-infectives in the effective treatment of MDR infections. This partnership enhances Cipla's commitment to AMR stewardship and strengthens our efforts to combat infectious diseases and deliver advanced, innovative therapies to patients." Both companies are committed to responsible antibiotic stewardship and will work closely with healthcare professionals to ensure appropriate use of this new antibiotic combination. 1 Educational initiatives and guidelines for prescribing will be developed to maximize the drug's benefits while minimizing the risk of further antimicrobial resistance. +++ About Orchid Pharma Limited : Established in 1992 as an export-oriented unit (EOU), Orchid Pharma Ltd. (Orchid) is a vertically integrated Company spanning the entire pharmaceutical value chain with established credentials in research, manufacturing, and marketing. Orchid, is the only Indian Pharmaceutical Company, to ever have invented a New Chemical Entity (NCE, also colloquially called New Drug). The molecule is out licensed (on Royalty model) and now approved in US and Europe. Orchid is a pioneer in Production of Quality Cephalosporins especially the Sterile Products, for which it is the one out of the only three USFDA approved facilities in the world, and the only one from India. Besides this, the facility has other approvals like EU GMP, ANVISA and PMDA. About Cipla: Established in 1935, Cipla is a global pharmaceutical company focused on agile and sustainable growth, complex generics, and deepening portfolio in our home markets of India, South Africa, North America, and key regulated and emerging markets. Our strengths in the respiratory, anti-retroviral, urology, cardiology, anti-infective and CNS segments are well-known. Our 47 manufacturing sites around the world produce 50+ dosage forms and 1,500+ products using cutting-edge technology platforms to cater to our 80+ markets. Cipla is ranked 3 rd largest in pharma in India (IQVIA MAT Mar'24), Largest in the pharma prescription market in South Africa (IQVIA MAT Mar'24), and 4 th largest by prescription in the US Gx inhalation products (IQVIA MAT Feb'24). For over eight decades, making a difference to patients has inspired every aspect of Cipla's work. Our paradigm-changing offer of a triple anti-retroviral therapy in HIV/AIDS at less than a dollar a day in Africa in 2001 is widely acknowledged as having contributed to bringing inclusiveness, accessibility and affordability to the centre of the HIV movement. A responsible corporate citizen, Cipla's humanitarian approach to healthcare in pursuit of its purpose of 'Caring for Life' and deep-rooted community links wherever it is present make it a partner of choice to global health bodies, peers and all stakeholders. For more, please visit www.cipla.com , or click on Twitter , Facebook , LinkedIn . For queries, please contact : Corporate Communications Investor Relations Heena Kanal Ajinkya Pandharkar E-Mail: [email protected] E-Mail: [email protected] 2

View stock analysis, news, and events for Cipla Ltd